MicroCap Monitor: One Quarter - Cynata's Defining Moment Approaches

Cynata features in the latest MicroCap Monitor Magazine examining two pivotal clinical trial readouts expected this quarter. The article covers the Phase 2 aGvHD trial (65 participants, results June 2026) and Phase 3 osteoarthritis trial (321 participants, results May 2026), explaining how the Cymerus™ platform produces consistent, highly potent MSCs from a single blood donation rather than requiring continuous donor sourcing.

CEO Dr Kilian Kelly: "Combined with the clinical data we've already generated and two major readouts now imminent, we believe Cynata is at an inflection point that very few biotechs ever reach."

Read the full article below.